Compare SGHT & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHT | SMTI |
|---|---|---|
| Founded | 2011 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.6M | 208.2M |
| IPO Year | 2021 | 2008 |
| Metric | SGHT | SMTI |
|---|---|---|
| Price | $5.43 | $24.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $9.08 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 175.8K | 57.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $77,363,000.00 | $15,586,976.00 |
| Revenue This Year | $11.67 | $17.31 |
| Revenue Next Year | $10.39 | $12.48 |
| P/E Ratio | ★ N/A | $496.80 |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $3.11 | $16.05 |
| 52 Week High | $9.24 | $35.70 |
| Indicator | SGHT | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 62.65 |
| Support Level | $4.76 | $20.47 |
| Resistance Level | $5.66 | $26.48 |
| Average True Range (ATR) | 0.36 | 1.38 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 56.86 | 97.59 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.